I think the distance that AGN has from the data at the moment is actually a good sign as it means that the analysis is going to be done in an independent/impartial manner (this appears to be consistent with best practice for clinical trials).
I have had moments where I have wondered if they have, through their recent focus now on DMT, essentially moved on from the covid trial, but i'm not sure this is fair. aside from providing more clarity on next steps, they probably are not in a position to know or say a whole lot more.
News 
Market Data 
Discover 
